The Oncology Institute, Inc. Common Stock
TOIThe Oncology Institute, Inc. (TOI) is a healthcare company focusing on providing specialized oncology care. It operates a network of outpatient clinics dedicated to the treatment of cancer, offering medical, radiation, and infusion services. The company emphasizes patient-centered care through a comprehensive approach, integrating advanced treatment options with supportive services.
Company News
M33 Growth, a Boston-based venture firm, announced a partnership with U.S. Neurology Associates (USNA), a physician services organization focused on community-based neurology care. Nitin Jain will serve as CEO and Brad Hively as Chairman. USNA aims to provide comprehensive, integrated neurological care including in-office infusions, diagnostics, ...
The Oncology Institute promoted Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. Panda brings 25+ years of IT and digital transformation experience from roles at Cisco and Infosys, while Mariano brings 18 years of People Operations experience. The promotions support TOI's growth in value-based cancer care and t...
The Oncology Institute (TOI) has seen a massive stock rally of over 950% in 2025, driven by its value-based cancer care approach, AI-driven operational efficiencies, and potential for growth across multiple states.
The Oncology Institute reported Q2 2025 revenue of $119.8 million, a 21.5% year-over-year increase, driven by strong pharmacy segment performance. Despite revenue growth, the company continues to face challenges with net losses and cash burn.
The Oncology Institute, Inc. (TOI) announced a $16.5 million private placement with existing investors, management, and directors. The proceeds will be used for organic growth and working capital. The company also entered an exchange agreement with Deerfield Management Company to exchange convertible notes for preferred stock and warrants.
